Shares of Recro Pharma REPH fell 7.4% in pre-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share were down 230.00% year over year to ($0.33), which missed the estimate of ($0.03).
Revenue of $21,777,000 lower by 13.12% from the same period last year, which beat the estimate of $19,450,000.
Outlook
Recro Pharma hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Recent Stock Performance
Company's 52-week high was at $19.21
Company's 52-week low was at $6.10
Price action over last quarter: down 18.09%
Company Description
Recro Pharma Inc is a contract development and manufacturing company. The company is engaged in the development, formulation, regulatory support, manufacturing, and packaging of oral solid dose drug products. Its product portfolio includes Ritalin LA; Focalin XR; Verelan PM, SR and Verapamil PM; Verapamil SR and Zohydro ER.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.